Description

This thematic volume provides authoritative, up-to-date reviews addressing recent advances as well as an overview for the research and clinical communities on the endemic infection of Chagas disease. Lead researchers discuss epidemiology and control measures as well as various diagnosis techniques, treatments, and therapies currently being used. The text includes a history of Chagas disease and an outlook for the next century.

 

Key Features

  • Informs and updates on all the latest developments in the field
  • Contributions from leading authorities and industry experts

Readership

Researchers in parasitology, tropical medicine and entomology.

Table of Contents

Series Editors

Contributors

Preface

Epidemiology of American Trypanosomiasis (Chagas Disease)

1.1. Historical Background

1.2. Mechanisms of Transmission of Trypanosoma cruzi

1.3. Epizootiology of Trypanosoma cruzi

1.4. Epidemiology of Human Trypanosoma cruzi Infection in the Endemic Countries

1.5. Epidemiology of Trypanosoma cruzi Infection in the United States

1.6. Trypanosoma cruzi Infection in Non-Endemic Countries Other than the United States

1.7. Perspectives on the Control of Chagas Disease

Acute and Congenital Chagas Disease

2.1. Introduction

2.2. Acute Phase

2.3. Clinical and Diagnostic Aspects of Congenital Trypanosoma cruzi Infection

2.4. Antitrypanosomal Drug Treatment

2.5. Epidemiology of Congenital Chagas Disease

2.6. Approaches to the Control of Congenital Chagas Disease

2.7. Conclusions

Cell-Based Therapy in Chagas Disease

3.1. Introduction

3.2. Cell Therapy in Cardiac Diseases

3.3. Cell Therapy in Chagas Disease

3.4. Clinical Trials

3.5. Future Perspectives for Cell-Based Therapies in Chagas Disease

Targeting Trypanosoma cruzi Sterol 14α-Demethylase (CYP51)

4.1. Introduction

4.2. Sterol Biosynthesis

4.3. Potential Drug Targets in the Pathway

4.4. Trypanosoma cruzi Sterol 14α-Demethylase (CYP51)

4.5. Inhibitors of Trypanosoma cruzi CYP51

4.6. Structural Basis for CYP51 Druggability

4.7. Anti-Parasitic Effects of CYP51 Inhibition in Trypanosoma cruzi

Acknowledgements

Experimental Chemotherapy and Approaches to Drug Discovery for Trypanosoma cruzi Infection

5.1. Introduction

5.2. Compound Selection

5.3. In Vitro Efficacy Testing

5.4. Toxicity Testing

5.5. In Vivo Efficacy Testing

5.6. Testing for Drug-Like Propertie

Details

No. of pages:
390
Language:
English
Copyright:
© 2011
Published:
Imprint:
Academic Press
Electronic ISBN:
9780123858641
Print ISBN:
9780123858634

About the serial-volume-editors

Louis M. Weiss

Louis M. Weiss M.D., M.P.H is Professor of Medicine (Division of Infectious Diseases) and Professor of Pathology (Division of Parasitology and Tropical Medicine) of the Albert Einstein College of Medicine, Bronx, New York. Dr. Weiss received his M.D. and M.P.H degrees from the Johns Hopkins University in 1982. He then completed a residency in Internal Medicine at the University of Chicago and a fellowship in Infectious Diseases at the Albert Einstein College of Medicine. Following this fellowship, he joined the faculty at Einstein where he is currently a Professor of Pathology and Medicine. His laboratory group has an active research program on parasitic diseases with a research focus on Toxoplasma gondii, the Microsporidia and Trypanosoma cruzi. Dr. Weiss is the author of over 200 publications and the editor of 3 books on parasitology. He is a fellow of the American College of Physicians, Infectious Disease Society of America and the American Academy of Microbiology. Dr. Weiss is the Co-Director of the Einstein Global Health Center.

Reviews

"One is struck by the quality and scholarship of the various chapters and the obviously efficient editing."
-PARASITOLOGY
"The policy of the editors of Advances in Parasitology to include reviews from any aspect of parasitology and the high standard of individual papers have resulted in this series of volumes becoming an indispensable source for students, teachers, and research workers."
-ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY